DMDaniel Marelli

Daniel Marelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Marelli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Seventeen-year experience with 1,083 heart transplants at a single institution

    by Daniel Marelli, Hillel Laks, Jon A Kobashigawa, Jessica Bresson, Abbas Ardehali, Fardad Esmailian, Mark D Plunkett, Bernard Kubak


  • Open Access

    Short‐Term Bridge to Heart Transplant Using the BVS 5000 External Ventricular Assist Device1,2

    by Feng-Chun Tsai, Daniel Marelli, Hillel Laks, Jaime Moriguchi, Michael Sopher, Jessica Bresson, Saleh Moghaddam, Barnard Kubak, Fardad Esmailian, Abbas Ardehali, et al.

    From January 1995 to April 2001, 71 patients with cardiogenic shock using the BVS 5000 were treated or accepted in transfer. Of the 24 transplanted, nine had dilated cardiomyopathy, ischemic cardiomy...


  • Open Access

    Hepatitis C‐positive Donors in Heart Transplantation

    by Daniel Marelli, Jessica Bresson, Hillel Laks, Bernard Kubak, Gregg Fonarow, Feng‐Chun Tsai, Julie Tran, Shiobhan R. Weston, Jon Kobashigawa

    Hepatitis C virus (HCV) can be transmitted to heart transplant recipients by donor organs. Mid‐term results were reported using HCV‐positive donors in patients at risk of imminent death (group I, n =...


  • Mechanical assist strategy using the BVS 5000i for patients with heart failure

    by Daniel Marelli, Hillel Laks, Daniel Fazio, Michele A Hamilton, Gregg C Fonarow, Deborah A Meehan, Jaime D Moriguchi


  • The use of donor hearts with left ventricular hypertrophy

    by Daniel Marelli, Hillel Laks, Daniel Fazio, Sara Moore, Jaime Moriguchi, Jon Kobashigawa


    • 1 January 2000
      • p. 297-310

    Sixteen-year experience with 1,000 heart transplants at UCLA.

    by D Marelli, H Laks, J Bresson, E Houston, D Fazio, F C Tsai, M Hamilton, J Moriguchi, G C Fonarow, A Ardehali, et al.

    1. The consecutive pre- and post-1994 eras have demonstrated improved survival for all age groups. This is linked to improved preservation methods, surgical technique and immunosuppression agents. 2. The use of marginal donor hearts for Status I and alternate elderly patients has followed the model of matching donor and recipient risk without affecting patient outcome and minimized the use of implantable assist devices. 3. A donor history of systemic gram-negative infection, hypertension, or traumatic intracranial bleeds was an important marker for risk. Younger age and shorter ischemia time could compensate for other hazards. 4. Heart transplantation in carefully selected elderly recipients yielded clinical results similar to those of younger patients with less rejection. 5. An adult alternate recipient list proved useful to prevent diversion of standard donors away from younger recipients. 6. Retransplantation for TCAD is acceptable but much less satisfactory for acute graft failure. 7. Trends show an increase in the use of implantable devices; refinement in technology for mechanical assist and replacement is forthcoming.

    • 1 March 1998
      • Vol. 17  (3) , 250-8

    Use of leukocyte depletion to decrease injury after lung preservation and rewarming ischemia: an experimental model.

    by Y Shiraishi, J R Lee, H Laks, P F Waters, A Meneshian, D Marelli, A Blitz, P Chang

    Hypothermia is critical for proper lung preservation. Ideally, the lungs should be maintained at the optimal preservation temperature during the entire ischemic interval. Lung rewarming during implantation is commonly observed. This study was undertaken to investigate the severity of rewarming ischemia on preservation injury and the possibility of minimizing this by use of leukocyte depletion during initial reperfusion. Four experimental groups were tested as follows: neonatal piglet heart-lung blocks were either (1) placed on an isolated, blood-perfused, working heart-lung circuit without intervening ischemia (control, n = 6), (2) reperfused on the circuit with whole blood (WB, n = 6) after 13 hours of preservation, (3) reperfused with WB after 12 hours of preservation and 1 hour of rewarming (RWB, n = 5), or (4) reperfused with leukocyte-depleted blood for an initial 10 minutes followed by WB, after 12 hours of preservation and 1 hour of rewarming (n = 6). All groups were studied for 4 hours. The partial pressure of arterial oxygen and lung compliance were significantly lower in the RWB group than in controls (113.8+/-33.1 vs 417.3+/-6.2 mm Hg, p < 0.01; and 0.8+/-0.2 vs 2.9+/-0.4 ml/cm H2O, p < 0.05, respectively). Pulmonary vascular resistance and lung wet/dry weight ratios were significantly higher in the RWB group than in controls (15884.1+/-11354.8 vs 6108.3+/-1309.9 dyne x sec x cm[-5], p < 0.05; and 7.13+/-0.24 vs 5.82+/-0.35, p < 0.05, respectively). The WB and leukocyte-depleted groups did not differ significantly from controls for any measured parameter. This model confirms that rewarming ischemia during lung implantation exacerbates reperfusion injury. Leukocyte-depleted reperfusion as tested for a short period of time (10 minutes) ameliorates this injury and therefore should be considered for clinical lung transplantation.

    • 1 January 1998
      • p. 303-10

    The University of California at Los Angeles experience in heart transplantation.

    by J A Kobashigawa, H Laks, D Marelli, J D Moriguchi, M A Hamilton, G Fonarow, A Hage, N Kawata

    In the last decade, the number of patients undergoing heart transplant has steadily increased as a result of expanding indications for this procedure. The limitation on the number of transplants performed has been the number of donor organs available. At UCLA, 900 heart transplant procedures have been performed from 1984-1998. Since 1991, the percent of patients free from rejection and infection in the first year after transplant was 70% and 73%, respectively. Actuarial one-, 3-, and 5-year survival rates are 84%, 76%, and 72%, respectively. Survival of patients aged 60 years and over (n = 105) was comparable to that of patients under age 60. We have been pursuing corticosteroid-free immunosuppression, which has led to a decrease in infection complications. Our work with pravastatin early after transplantation has led to a decrease in clinically severe rejection episodes, which has translated into improved survival. Pravastatin also appears to decrease the development of transplant coronary artery disease and appears to have an adjunct immunosuppressive effect in our heart transplant patients on CsA-based immunosuppression. We have also demonstrated benefit of cardiac rehabilitation early after transplant which should therefore be considered as standard postoperative care. Finally, we have participated and led the multicenter mycophenolate study in demonstrating this drug's effectiveness in improved outcomes in primary heart transplant recipients. Future studies include the use of Rapamycin and interleukin-2 receptor blockers which have been demonstrated in kidney transplantation to significantly reduce rejection. Our program is committed to seek better ways to improve outcome and the quality of life of our heart transplant patients.